Confluent earnings beat, revenue fell short of estimates

Confluent (CFLT) reported mixed Q2 results, with EPS of $0.09 exceeding analyst estimates while revenue of $270.8M missed consensus. More significantly, the company issued weaker-than-expected revenue guidance for both Q3 2025 ($281.00M-$282.00M vs. $292.50M consensus) and full-year 2025 ($1.10B-$1.11B vs. $1.15B consensus). This downward revision in forward revenue outlook could temper investor sentiment despite the stock's recent 33.10% gain over the past three months.

Analysis

Confluent (CFLT) delivered mixed second-quarter results characterized by a minor earnings beat but a more significant revenue miss and weak forward guidance. While quarterly EPS came in at $0.09, narrowly surpassing the analyst estimate of $0.08, revenue of $270.8M fell short of the $278.29M consensus. The primary concern for investors stems from the company's forward-looking statements. Confluent's revenue guidance for Q3 2025 is set at $281.00M-$282.00M, substantially below the consensus of $292.50M. This weakness extends to the full-year 2025 forecast, which was revised down to $1.10B-$1.11B against a prior consensus of $1.15B. This negative outlook is particularly impactful as it follows a period of strong stock performance, with a 33.10% gain over the last three months, suggesting that market expectations were high. The disappointing revenue forecast, which overshadows the in-line Q3 EPS guidance, signals a potential deceleration in growth that conflicts with the recently positive trend of 17 upward EPS revisions from analysts.

Key Decisions for Investors

• Given the significant downward revision in revenue guidance for both the upcoming quarter and the full fiscal year, investors should anticipate near-term pressure on the stock, particularly following its 33.10% rally in the last three months.
• The market will likely weigh the substantial revenue guidance miss more heavily than the marginal Q2 EPS beat, so investors should focus on any future management commentary regarding the drivers of this expected slowdown.
• The weak outlook, which contrasts with the 17 positive analyst EPS revisions over the past 90 days, warrants a re-evaluation of the stock's growth thesis and valuation multiples.